MedPath

GnRH Agonist and Intrauterine Insemination

Phase 4
Completed
Conditions
Intrauterine Insemination
Registration Number
NCT00503217
Lead Sponsor
Instituto Valenciano de Infertilidad, IVI VALENCIA
Brief Summary

The aim of this study is to assess whether GnRH agonist administration in the luteal phase improves pregnancy outcome in intrauterine insemination (IUI) cycles.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
Not specified
Inclusion Criteria
  • Women < 38 years old
  • Bilateral tubal patency confirmed by hysterosonography
  • Normal ultrasound scan of uterus and ovaries
  • Normal day 3 basal hormones
  • Motile sperm count after capacitation ≥ 3 mill/ml
Exclusion Criteria
  • Endometriosis
  • Polycystic ovary syndrome
  • Uterine disease (polyps, myomas and müllerian diseases)

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Instituto Valenciano de Infertilidad Spain

🇪🇸

Valencia, Spain

© Copyright 2025. All Rights Reserved by MedPath